?> OBD Archives - Page 4 of 18 - DirectorsTalk

OBD

Oxford BioDynamics

EpiSwitch technology

EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs can provide a compelling, stable framework from

Oxford BioDynamics

What is ALS?

ALS, also known as Motor Neuron Disease (MND), Lou Gehrig’s Disease, and Charcot’s disease, is a progressive neurodegenerative disease which attacks motor neurons in the brain and spinal cord resulting

Oxford BioDynamics

Oxford Biodynamics publish Annual Report

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announced

Oxford BioDynamics

What is EpiSwitchTM and how is it used?

Grounded in Epigenetics Oxford BioDynamics’ EpiSwitch technology is based on epigenetics: mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the

Oxford BioDynamics

What is ALS?

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disease that destroys nerve cells in the brain  and the spinal cord and causes disability. It is also known as Lou Gehrig’s disease. The

Oxford BioDynamics

Insurance Data May Predict ALS, Research Shows

A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis of the disease in others, research suggests. The findings were presented at the 30th

Oxford BioDynamics

‘Jumping Genes’ Identified as Possible Cause of ALS

A new study identified a group of sporadic amyotrophic lateral sclerosis (ALS) patients whose disease may arise from a group of “jumping genes” unleashed when TDP-43 protein accumulates in clumps in the brain and